Framingham, MA, United States of America

Bryce Alden Harrison

USPTO Granted Patents = 19 (Patent Applications = 10)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 18)

Average Co-Inventor Count = 10.8

ph-index = 4

Forward Citations = 44(Granted Patents)

Company Filing History:

15 out of 15

Morphic Therapeutic, Inc.

patents

3 out of 8

Axovant Sciences Gmbh

patents

1 out of 51

Denali Therapeutics Inc.

patents

Years Active: 2017-2025

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12459942 - Inhibiting (α-v)(β-6) integrin (2025-11-04),

2. 12415796 - Inhibitors of (αv)(β6) integrin (2025-09-16),

3. 12221416 - Antagonists of human integrin α4β7 (2025-02-11),

4. 12145935 - Inhibitors of (α-v)(β-6) integrin (2024-11-19),

5. 11827621 - Inhibitors of (α-v)(β-6) integrin (2023-11-28),

6. 11795167 - Inhibitors of (α-v)(β-6) integrin (2023-10-24),

7. 11739087 - Inhibiting (α-v)(β-6) integrin (2023-08-29),

8. 11370773 - Inhibiting human integrin (alpha-4) (beta-7) (2022-06-28),

9. 11174228 - Antagonists of human integrin (α4)(β7) (2021-11-16),

10. 11104661 - Inhibiting human integrin (α-4) (β-7) (2021-08-31),

11. 11046685 - Inhibitors of (α-v)(β-6) integrin (2021-06-29),

12. 11046669 - Inhibitors of (α-v)(β-6) integrin (2021-06-29),

13. 11040955 - Inhibitors of (alpha-v)(beta-6) integrin (2021-06-22),

14. 11021480 - Inhibiting (α-V)(β-6) integrin (2021-06-01),

15. 10759756 - Antagonists of human integrin α4β7 (2020-09-01),

Title: Innovations and Contributions of Bryce Alden Harrison

Introduction

Bryce Alden Harrison is a notable inventor based in Framingham, MA (US). He has made significant contributions to the field of integrin inhibitors, holding a total of 18 patents. His work focuses on developing small molecule inhibitors and antagonists that have the potential to treat various diseases and conditions.

Latest Patents

Among his latest patents are the inhibitors of αvβ6 integrin, which are small molecules designed to target this specific integrin. These inhibitors are disclosed for their methods of use in treating a range of diseases. Additionally, he has developed antagonists of human integrin α4β7, which are also small molecules aimed at treating specific diseases or conditions.

Career Highlights

Bryce has worked with several prominent companies in the biotechnology sector, including Morphic Therapeutics, Inc. and Axovant Sciences GmbH. His experience in these organizations has allowed him to advance his research and contribute to innovative therapeutic solutions.

Collaborations

Some of his notable coworkers include Matthew Gregory Bursavich and Aleksey I. Gerasyuto. Their collaborative efforts have further enhanced the research and development of integrin-targeted therapies.

Conclusion

Bryce Alden Harrison's work in the field of integrin inhibitors showcases his dedication to advancing medical science through innovation. His patents and collaborations reflect a commitment to developing effective treatments for various health conditions.

This text is generated by artificial intelligence and may not be accurate.